Wall Street analysts expect Trillium Therapeutics Inc (NASDAQ:TRIL) (TSE:TR) to announce earnings per share of ($0.66) for the current quarter, Zacks Investment Research reports. Zero analysts have made estimates for Trillium Therapeutics’ earnings. The highest EPS estimate is ($0.59) and the lowest is ($0.78). Trillium Therapeutics posted earnings per share of ($0.72) during the same quarter last year, which would indicate a positive year-over-year growth rate of 8.3%. The business is scheduled to report its next quarterly earnings report on Friday, March 8th.
On average, analysts expect that Trillium Therapeutics will report full-year earnings of ($2.47) per share for the current year, with EPS estimates ranging from ($2.52) to ($2.42). For the next financial year, analysts anticipate that the company will report earnings of ($2.04) per share, with EPS estimates ranging from ($2.43) to ($1.34). Zacks Investment Research’s EPS calculations are a mean average based on a survey of analysts that that provide coverage for Trillium Therapeutics.
Several equities research analysts have recently commented on the stock. Zacks Investment Research cut shares of Trillium Therapeutics from a “buy” rating to a “hold” rating in a research report on Wednesday, November 21st. HC Wainwright reiterated a “buy” rating and set a $10.00 price target on shares of Trillium Therapeutics in a research report on Monday, August 13th.
Shares of NASDAQ:TRIL traded down $0.22 during trading on Monday, hitting $2.03. 54,646 shares of the company’s stock were exchanged, compared to its average volume of 80,434. Trillium Therapeutics has a 1-year low of $2.01 and a 1-year high of $11.50. The company has a debt-to-equity ratio of 0.01, a current ratio of 4.33 and a quick ratio of 4.33. The stock has a market cap of $33.05 million, a price-to-earnings ratio of -0.57 and a beta of 2.39.
Several large investors have recently modified their holdings of TRIL. Wealth Alliance Advisory Group LLC acquired a new position in Trillium Therapeutics during the third quarter valued at approximately $126,000. Stanley Laman Group Ltd. grew its holdings in Trillium Therapeutics by 26.7% during the second quarter. Stanley Laman Group Ltd. now owns 137,091 shares of the biotechnology company’s stock valued at $823,000 after purchasing an additional 28,907 shares during the period. Renaissance Technologies LLC grew its holdings in Trillium Therapeutics by 245.3% during the second quarter. Renaissance Technologies LLC now owns 144,000 shares of the biotechnology company’s stock valued at $864,000 after purchasing an additional 102,300 shares during the period. Morgan Stanley grew its holdings in Trillium Therapeutics by 25.2% during the third quarter. Morgan Stanley now owns 356,655 shares of the biotechnology company’s stock valued at $2,068,000 after purchasing an additional 71,860 shares during the period. Finally, Baker BROS. Advisors LP grew its holdings in Trillium Therapeutics by 25.0% during the second quarter. Baker BROS. Advisors LP now owns 511,763 shares of the biotechnology company’s stock valued at $3,071,000 after purchasing an additional 102,440 shares during the period. Institutional investors own 47.47% of the company’s stock.
Trillium Therapeutics Company Profile
Trillium Therapeutics Inc, a clinical-stage immuno-oncology company, develops therapies for the treatment of cancer. The company's lead program is TTI-621, a SIRPaFc fusion protein that acts a soluble decoy receptor preventing CD47 from delivering its inhibitory signal, which is in Phase I clinical trial for advanced hematologic malignancies, and solid tumors and mycosis fungoides.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Trillium Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Trillium Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.